RODRIGO ABENSUR ATHANAZIO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
20 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 20
- 2018 recommendations for the management of community acquired pneumonia(2019) CORREA, Ricardo de Amorim; COSTA, Andre Nathan; LUNDGREN, Fernando; MICHELIN, Lessandra; FIGUEIREDO, Mara Rubia; HOLANDA, Marcelo; GOMES, Mauro; TEIXEIRA, Paulo Jose Zimermann; MARTINS, Ricardo; SILVA, Rodney; ATHANAZIO, Rodrigo Abensur; SILVA, Rosemeri Maurici da; PEREIRA, Monica Corso
- Use of elexacaftor plus tezacaftor plus ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis(2023) SILVA FILHO, Luiz Vicente Ribeiro Ferreira da; ATHANAZIO, Rodrigo Abensur; TONON, Carolina Rodrigues; FERREIRA, Juliana Carvalho; TANNI, Suzana EricoObjective: To evaluate the effect of treatment with the combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators-elexacaftor+tezac aftor+ivacaftor (ETI)-on important clinical endpoints in individuals with cystic fibrosis. Methods: This was a systematic review and meta-analysis of randomized clinical trials that compared the use of ETI in individuals with CF and at least one F508del allele with that of placebo or with an active comparator such as other combinations of CFTR modulators, following the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) recommendations and the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) methodology. We searched the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov from their inception to December 26th, 2022. The risk of bias was assessed using the Cochrane risk-of-bias tool, and the quality of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We retrieved 54 studies in the primary search. Of these, 6 met the inclusion criteria and were analyzed (1,127 patients; 577 and 550 in the intervention and control groups, respectively). The meta-analysis revealed that the use of ETI increased FEV 1% [risk difference (RD), +10.47%; 95% CI, 6.88-14.06], reduced the number of acute pulmonary exacerbations (RD, -0.16; 95% CI, -0.28 to -0.04), and improved quality of life (RD, +14.93; 95% CI, 9.98-19.89) and BMI (RD, +1.07 kg/m(2); 95% CI, 0.90-1.25). Adverse events did not differ between groups (RD, -0.03; 95% CI, -0.08 to 0.01), and none of the studies reported deaths. Conclusions: Our findings demonstrate that ETI treatment substantially improves clinically significant, patientcentered outcomes.
- A study of the psychometric properties of the Brazilian-Portuguese version of Bronchiectasis Health Questionnaire(2023) LUPPO, A.; CAMARGO, C. O. de; BIRRING, S. S.; LUNARDI, A. C.; RACHED, S. Z.; ATHANAZIO, R. A.; STELMACH, R.; CORSO, S. D.Introduction and objective: The Bronchiectasis Health Questionnaire (BHQ) is a simple, repeatable, and self-reporting health status questionnaire for bronchiectasis. This study aims to cross-culturally adapt the BHQ into Brazilian Portuguese and evaluate its measurement properties.Methods: The participants answered the Saint George's Respiratory Questionnaire (SGRQ) and the modified Medical Research Council (mMRC) scale for dyspnea. The Brazilian-Portuguese version of the Bronchiectasis Health Questionnaire (BHQ-Brazil) was used at baseline (test) and after 14 days (retest). The psychometric analyses included internal consistency, test-retest reliability, and construct validity: factorial validity, convergent validity, and discriminative validity, agreement, and ceiling and floor effects. Results: The BHQ-Brazil demonstrated adequate internal consistency (Cronbach's alpha = 0.92) and substantial reliability (intraclass correlation coefficient = 0.86; 95%CI: 0.79--0.90). The exploratory factorial analysis was considered suitable. All items presented a factorial load >0.40. The convergent validity of the BHQ-Brazil with mMRC was moderate (r = -0.53, p < 0.001), while concurrent validity with the SGRQ was strong (symptoms: r = -0.72, activities: r = -0.60, impact: r = -0.60, total score: r = -0.75, all p < 0.001). The standard error of measurement was 4.81 points. The discriminative validity demonstrated that individuals with more pulmonary exacerbations, colonization by Pseudomonas aeruginosa, worst dyspnea, and a higher number of affected lung lobes presented the lowest quality of life. No floor or ceiling effects were observed.Conclusion: The BHQ-Brazil presents adequate measurement properties to evaluate the impact of bronchiectasis on health-related quality of life, and can be used in clinical and research settings.(c) 2020 Sociedade Portuguesa de Pneumologia.
- In-person and online application of the Bronchiectasis Health Questionnaire: are they interchangeable?(2022) LUPPO, Adriano; RACHED, Samia Z.; ATHANAZIO, Rodrigo A.; STELMACH, Rafael; CORSO, Simone Dal
- Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)(2023) ATHANAZIO, Rodrigo Abensur; TANNI, Suzana Erico; FERREIRA, Juliana; DALCIN, Paulo de Tarso Roth; FUCCIO, Marcelo B. de; ESPOSITO, Concetta; CANAN, Mariane Goncalves Martynychen; COELHO, Liana Sousa; FIRMIDA, Monica de Cassia; ALMEIDA, Marina Buarque de; MAROSTICA, Paulo Jose Cauduro; MONTE, Luciana de Freitas Velloso; SOUZA, Edna Lucia; PINTO, Leonardo Araujo; RACHED, Samia Zahi; OLIVEIRA, Veronica Stasiak Bednarczuk de; RIEDI, Carlos Antonio; SILVA FILHO, Luiz Vicente Ribeiro Ferreira daCystic fibrosis (CF) is a genetic disease that results in dysfunction of the CF transmembrane conductance regulator (CFTR) protein, which is a chloride and bicarbonate channel expressed in the apical portion of epithelial cells of various organs. Dysfunction of that protein results in diverse clinical manifestations, primarily involving the respiratory and gastrointestinal systems, impairing quality of life and reducing life expectancy. Although CF is still an incurable pathology, the therapeutic and prognostic perspectives are now totally different and much more favorable. The purpose of these guidelines is to define evidence- based recommendations regarding the use of pharmacological agents in the treatment of the pulmonary symptoms of CF in Brazil. Questions in the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) format were employed to address aspects related to the use of modulators of this protein (ivacaftor, lumacaftor+ivacaftor, and tezacaftor+ivacaftor), use of dornase alfa, eradication therapy and chronic suppression of Pseudomonas aeruginosa, and eradication of methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex. To formulate the PICO questions, a group of Brazilian specialists was assembled and a systematic review was carried out on the themes, with meta-analysis when applicable. The results obtained were analyzed in terms of the strength of the evidence compiled, the recommendations being devised by employing the GRADE approach. We believe that these guidelines represent a major advance to be incorporated into the approach to patients with CF, mainly aiming to favor the management of the disease, and could become an auxiliary tool in the definition of public policies related to CF.
- Automated Computed Tomography Lung Densitometry in Bronchiectasis Patients(2022) SAWAMURA, Marcio Valente Yamada; ATHANAZIO, Rodrigo Abensur; NUCCI, Maria Cecilia Nieves Teixeira Maiorano de; RACHED, Samia Zahi; CUKIER, Alberto; STELMACH, Rafael; ASSUNCAO- JR., Antonildes Nascimento; TAKAHASHI, Marcelo Straus; NOMURA, Cesar Higa
- A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia(2023) KOS, Renate; GOUTAKI, Myrofora; KOBBERNAGEL, Helene E.; RUBBO, Bruna; SHOEMARK, Amelia; ALIBERTI, Stefano; ALTENBURG, Josje; ANAGNOSTOPOULOU, Pinelopi; ATHANAZIO, Rodrigo A.; BEYDON, Nicole; DELL, Sharon D.; EMIRALIOGLU, Nagehan; FERKOL, Thomas W.; LOEBINGER, Micael R.; LORENT, Natalie; MAITRE, Bernarnd; MARTHIN, June K.; MORGAN, Lucy C.; NIELSEN, Kim G.; RINGHAUSEN, Felix C.; SHTEINBERG, Michal; TIDDENS, Harm A. W. M.; ZEE, Anke H. Maitland-Van Der; CHALMERS, James D.; LUCAS, Jane S. A.; HAARMAN, Eric G.
- Recommended for the management of pneumonia acquired in the community 2018 (vol, 45, pg, 405, 2018)(2018) CORREA, Ricardo de Amorim; COSTA, Andre Nathan; LUNDGREN, Fernando; MICHELIN, Lessandra; FIGUEIREDO, Mara Rubia; HOLANDA, Marcelo; GOMES, Mauro; TEIXEIRA, Paulo Jose Zimermann; MARTINS, Ricardo; SILVA, Rodney; ATHANAZIO, Rodrigo Abensur; SILVA, Rosemeri Maurici da; PEREIRA, Monica Corso
- Post-TB bronchiectasis: from pathogenesis to rehabilitation(2023) MARTINEZ-GARCIA, M. A.; GUAN, W-j.; DE-LA-ROSA, D.; ATHANAZIO, R.; OSCULLO, G.; SHI, M-x.; PUJAL-MONTANA, P.; ENDLICH, B. N.; TIBERI, S.; CENTIS, R.; MIGLIORI, G. B.The destruction of lung parenchyma caused by TB can result in pulmonary sequelae that are classified as bronchiectasis due to traction (radiological sequelae), and bronchiectasis persisting with an inflammatory bronchial component and opportunistic bronchial infec-tion. There is a lack of studies that comprehensively analyse whether post-TB bronchiectasis differs in clinical, prognostic or therapeutic aspects from bronchiectasis arising from other aetiologies. However, it has been noted that post-TB bronchiectasis tends to appear more frequently in the upper lung lobes. In many countries, TB is the most frequent known cause of bronchiectasis, but there is currently no targeted management of bronchiectasis due to TB as opposed to other aetiologies. It is imperative to first prevent TB, and when that fails to provide early diagnosis and adequate treatment for TB disease. In addition, efforts should be made to limit additional lung insults such as tobacco use and provide management of post TB bronchiectasis to minimise further pulmonary sequelae. The objective of this minire-view was to provide an update on post-TB bronchiectasis, its definition, epidemiological data, pathophysiology, and clinical, diagnosis and therapeutic aspects.
- Is cystic fibrosis a risk factor for COVID-19 infection or related complications?(2022) ATHANAZIO, Rodrigo A.